Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9H2K0
UPID:
IF3M_HUMAN
Alternative names:
-
Alternative UPACC:
Q9H2K0; Q05BL8; Q5W0V0; Q86X68
Background:
Translation initiation factor IF-3, mitochondrial, identified by the accession number Q9H2K0, plays a pivotal role in protein synthesis. It binds to the 28S ribosomal subunit, facilitating the separation of 55S ribosomes into 39S and 28S subunits. This process enhances the availability of 28S subunits, which are essential for the initiation of protein synthesis.
Therapeutic significance:
Understanding the role of Translation initiation factor IF-3, mitochondrial could open doors to potential therapeutic strategies.